Wednesday, May 03, 2017

DermWireTV: Skin Cancer Prevention, Mohs Data, Allergan Closes on Zeltiq

It's Skin Cancer Awareness Month. Joel L. Cohen, MD and Shadi Kourosh, MD share tips on patient education and skin protection. Plus, new data set the stage for developing best practices for Mohs micrographic surgery. Wendy Lewis offers tips for digital marketing success. Plus, Allergan closes the deal on Zeltiq.

Watch Video

Tuesday, April 25, 2017

DermWireTV: AAD & Week of Science, ADCETRIS CTCL Data, SILIQ Pricing

It's the Week of Science. The American Academy of Dermatology has joined a large group of other medical group in supporting the March for Science and its principles. Adults with hyperpigmentation tend to use sunscreen, but they are less likely to use other UV avoidance strategies, new research in JAAD shows. In the Phase 3 ALCANZA trial, Seattle Genetics’ and Takeda’s ADCETRIS was associated with a statistically significant improvement in the objective response rate in subjects with CTCL. Valeant Pharmaceuticals’ SILIQ injection of brodalumab will be priced at $3,500 per month, making it the least expensive injectable biologic psoriasis treatment currently on the market, the company says.

Watch Video

Thursday, April 13, 2017

DermWireTV: Rhatigan to Merz, MOC Dissatisfaction, Syneron-Candela Sale

Industry veteran Bob Rhatigan is the new President and Chief Executive Officer of Merz North America. Patrick Urban is new Chief Commercial Officer. In a transaction valued at approximately $397 million, an affiliate of funds advised by Apax Partners will acquire all of the outstanding shares of Syneron Candela for $11.00 per share in cash. Hollywood has a “tendency to depict skin disease in an evil context,” authors of a new JAMA Dermatology analysis of famous movie heroes and villains conclude. PLUS: An update on anti-MOC efforts, with comment from H.L. Greenberg, MD.

Watch Video

Wednesday, March 29, 2017

DermWireTV: Dupixent, Juvéderm Vollure XC, Bavencio Approvals

The FDA has approved Regeneron’s injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan’s Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects saw improvement in moderate to severe nasolabial folds for up to 18 months. EMD Serono’s Bavencio (avelumab) has received FDA fast-track approval for treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma. And research shows no significant difference in outcomes when topical or oral antibiotics are added to standard eczema treatment with steroid creams and emollients.

Watch Video

Thursday, March 16, 2017| , AAD, , Galderma, , Modernizing Medicine,

DermWireTV: AAD SkinSerious Campaign, Meeting Highlights; Galderma Partners with Modernizing Medicine

The American Academy of Dermatology’s new SkinSerious campaign is raising awareness about skin disease and the specialty. The Skin Serious initiative kicked off at the AAD Annual Meeting in Orlando this month. New research presented at this year’s meeting focused on skin disease prevention and treatment. Galderma and Moderning Medicine are teaming up for a new integrated OTC ecommerce platform designed by Modernizing Medicine to make it easier for healthcare providers to create materials about patient treatment regimens and provide product recommendations to patients. Pershing Square Capital Management—for which Bill Ackman is CEO—has sold its investment in Valeant Pharmaceuticals International.

Watch Video

Thursday, February 23, 2017

DermWireTV: Valeant's Siliq Cleared, AmSpa Survey, New Skin Cancer Imaging

The FDA has approved Valeant Pharmaceutical's Siliq (brodalumab) injection for subcutaneous use for patients with moderate-to-severe plaque psoriasis. The American Med Spa Association (AmSpa) has extended the deadline for its comprehensive survey of MedSpas nationwide. Multiphoton microscopy of mitochondria, a new non-invasive imaging technique, may accurately detect skin cancer without surgical biopsy. And we'll see you at the AAD.

Watch Video

Wednesday, February 08, 2017| , Galderma, , Valeant NJ, , Zeltiq,

Galderma's Differin Goes OTC, CoolSculpting Approved for Upper Arms, ZO Skin Acquires ReFissa

Galderma’s Differin Gel formulation of adapalene 0.1% is now available over the counter at major retail and drug stores in the US. ZELTIQ® Aesthetics’ CoolSculpting is now FDA-cleared for fat reduction in the upper arms. ZO Skin Health has acquired the worldwide rights to ReFissa from Suneva Medical. Valeant Dermatology will be awarding nine individual scholarships of up to $10,000 through its annual ASPIRE HIGHER Scholarship Program.

Watch Video

Thursday, January 26, 2017

DermWireTV: Rhofade Approved, Sun Leaves Acne Behind, Radiesse Turns 10

The FDA has approved Allergan's Rhofade (Oxymetazoline 1%) cream for the topical treatment of persistent facial erythema associated with rosacea in adults. New research from Olay in collaboration with personal genetics company 23andMe shows that taking care of the skin may be the key to looking up to 10 years younger. Research from Johnson & Johnson suggests that the combined use of sunscreen and a beach umbrella may be the best bet for skin protection. Sun Pharma is urging patients to “Leave Acne Behind with an awareness campaign for severe recalcitrant nodular acne (SRNA). With more than 6 million syringes sold worldwide, Radiesse from Merz Aesthetics marks its 10-year anniversary this year.

Watch Video

Thursday, January 12, 2017| , L'oreal, , Valeant NJ,

DermWireTV: L'Oreal Nabs CeraVe, Smart Beauty Tools, Skin Cancer Knowledge Lacking

Researchers from La Roche-Posay and the George Washington University Department of Dermatology find that citizens in Australia, Ireland, Brazile, and Greece are best educated about UV exposure risks. Americans scored about average, said study author Dr. Adam Friedman. Valeant has agreed to sell its CeraVe, AcneFree, and Ambi lines to L’oreal for 1.3 billion dollars in cash. Kérastase and Withings nabbed this year's International CES Innovation Award with The Kérastase Hair Coach Powered. HiMirror rolled out a new Plus edition. Samsung’s S-Skin “microneedle” patch penetrates the skin with ingredients and simultaneously captures measurements of skin quality.

Watch Video

Monday, December 19, 2016| , Galderma, , Valeant NJ,

DermWireTV: Humphries to Valeant, Restylane Line Expands, 2016 Highlights

The filler market in the US expands with FDA approval of Galderma’s Restylane Refyne and Restalyne Define for the treatment of nasolabial folds in patients over the age of 21. The gels are manufactured with XpresHAn Technology, which allows a range of flexibility and support for varied patient needs, the company says. Dermatology industry veteran William D. Humphries has been appointed Executive Vice President, Dermatology, at Valeant Pharmaceuticals effective January 2. And as 2016 comes to a close, we take a look at some of the notable approvals of the year.

Watch Video

Thursday, December 08, 2016| , Cosmetic surgery, , Cosmetic Surgery Forum,

DermWireTV: Michael Gold Honored, CSF Highlights, Anxiety Linked to Skin Disease

From bloodless blephs to nutraceuticals, innovative approaches to patient care take the spotlight at Cosmetic Surgery Forum each year. This year, the meeting introduced new topics and new speakers, says CSF founder and Practical Dermatology Chief Cosmetic Surgery Editor, Dr. Joel Schlessinger. Dr. Michael H. Gold, and leader in the application of dermatologic devices is this year’s recipient of the Lifetime Contribution to Aesthetics Award at Cosmetic Surgery Forum. The link between anxiety and skin disease is gaining new attention. Researchers have shown that skin disorders tend to crop up in teens after they manifest anxiety disorders. Banning indoor tanning for minors in the US could save millions of dollars and save thousands of lives, a new analysis suggests.

Watch Video

Thursday, November 10, 2016| , Eczema, , Psoriasis,

DermWireTV: Enbrel Gets Nod for Pediatric PsO; IL-33 Targeted in Itch

FDA approved Amgen's Enbrel (etanercept) for chronic moderate to severe psoriasis in pediatric patients age 4 to 17. DermCheck App partners with anti-bullying groups Pacer and Not In My Town to help fight bullying and expand acne care. Researchers show that anti-IL-33 antibody reduces itch of poison ivy in mice, and look ahead to human applications in dermatitis, eczema, and psoriasis.

Watch Video
Load More